Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors

International Journal of Cancer

Volumn 137, Issue 8, 2015, Pages 1910-1920

  Boonstra, Martin C ^a   Tolner, Berend ^b   Schaafsma, Boudewijn E ^a   Boogerd, Leonora S F ^a   Prevoo, Hendrica A J M ^a   Bhavsar, Guarav ^b   Kuppen, Peter J K ^a   Sier, Cornelis F M ^a   Bonsing, Bert A ^a   Frangioni, John V ^c,d   Van De Velde, Cornelis J H ^a   Chester, Kerry A ^b   Vahrmeijer, Alexander L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Curadel   (United States)

Author keywords

CEACAM5; clinical translation; image guided; NIR fluorescence; surgery

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SSSM3E ANTIBODY; TRACER; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; IRDYE 800CW;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL ASSAY; COLORECTAL TUMOR; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; MOUSE; NEAR INFRARED FLUORESCENCE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; ANIMAL; ANTIBODY SPECIFICITY; CACO 2 CELL LINE; CANCER TRANSPLANTATION; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG SCREENING; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; BENZENESULFONATES; CACO-2 CELLS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG EVALUATION, PRECLINICAL; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; SINGLE-CHAIN ANTIBODIES; SPECTROSCOPY, NEAR-INFRARED;

EID: 84938956461     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29571     Document Type: Article

References (53)

1. Nagtegaal ID, Quirke P,. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-12.
2. Stefanidis D, Grove KD, Schwesinger WH, et al., The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 2006; 17: 189-99.
3. Weissleder R, Pittet MJ,. Imaging in the era of molecular oncology. Nature 2008; 452: 580-9.
4. Verhaar MJ, Chester KA, Keep PA, et al., A single chain fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 1995; 61: 497-501.
5. Begent RH, Verhaar MJ, Chester KA, et al., Clinical evidence of efficient tumor targeting based on single-chain fv antibody selected from a combinatorial library. Nat Med 1996; 2: 979-84.
6. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44: 1962-9.
7. Vahrmeijer AL, Hutteman M, van der Vorst JR, et al., Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013; 10: 507-18.
8. Nguyen QT, Tsien RY,. Fluorescence-guided surgery with live molecular navigation-a new cutting edge. Nat Rev Cancer 2013; 13: 653-62.
9. Hammarstrom S,. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
10. Kuespert K, Pils S, Hauck CR,. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006; 18: 565-71.
11. Tiernan JP, Perry SL, Verghese ET, et al., Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer 2013; 108: 662-7.
12. Vogel CA, Bischof-Delaloye A, Mach JP, et al., Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer 1993; 68: 684-90.
13. Lutje S, Franssen GM, Sharkey RM, et al., Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors. Bioconjug Chem 2014; 25: 335-41.
14. Girgis MD, Olafsen T, Kenanova V, et al., Targeting CEA in pancreas cancer xenografts with a mutated scFv-fc antibody fragment. EJNMMI Res 2011; 1: 24.
15. Mayer A, Tsiompanou E, O'Malley D, et al., Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain fv antibody. Clin Cancer Res 2000; 6: 1711-19.
16. Chester KA, Mayer A, Bhatia J, et al., Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 2000; 46 Suppl: S8 -S 12.
17. Vigor KL, Kyrtatos PG, Minogue S, et al., Nanoparticles functionalized with recombinant single chain fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 2010; 31: 1307-15.
18. Aarts F, Boerman OC, Sharkey RM, et al., Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody. Cancer 2010; 116: 1111-17.
19. Schoffelen R, van der Graaf WT, Sharkey RM, et al., Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res 2012; 2: 5.
20. Schoffelen R, Boerman OC, Goldenberg DM, et al., Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer 2013; 109: 934-42.
21. Pelegrin A, Folli S, Buchegger F, et al., Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer 1991; 67: 2529-37.
22. Lisy MR, Goermar A, Thomas C, et al., In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology 2008; 247: 779-87.
23. Cuesta AM, Sanchez-Martin D, Sanz L, et al., In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One 2009; 4: e5381.
24. Metildi CA, Kaushal S, Pu M, et al., Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol 2014; 4: 1505-11.
25. Boehm MK, Corper AL, Wan T, et al., Crystal structure of the anti-(carcinoembryonic antigen) single-chain fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 2000; 346 (Part 2): 519-28.
26. Sharma SK, Pedley RB, Bhatia J, et al., Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 2005; 11: 814-25.
27. Mayer A, Francis RJ, Sharma SK, et al., A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein mfecp1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 2006; 12: 6509-16.
28. Graff CP, Chester K, Begent R, et al., Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 2004; 17: 293-304.
29. Tolner B, Bhavsar G, Foster B, Vigor K, ester KA,. Chapter-37: Production of Recombinant Proteins from Pichia pastoris: Interfacing Fermentation and Immobilized Metal Ion Affinity Chromatography. Laboratory Protocols in Fungal Biology; (Eds.). Springer Science & Business Media; London, UK 2012.
30. Tolner B, Smith L, Begent RH, et al., Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc 2006; 1: 1006-21.
31. Brinkmann U, Gallo M, Brinkmann E, et al., A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the fv region of monoclonal antibody pr1 and a truncated form of pseudomonas exotoxin. Proc Natl Acad Sci USA 1993; 90: 547-51.
32. Reiter Y, Brinkmann U, Jung SH, et al., Disulfide stabilization of antibody fv: computer predictions and experimental evaluation. Protein Eng 1995; 8: 1323-31.
33. Schumacher FF, Sanchania VA, Tolner B, et al., Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'. Sci Rep 2013; 3: 1525.
34. Verbeek FP, van der Vorst JR, Tummers QR, et al., Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann Surg Oncol 2014; 21: 528-37.
35. Oliveira S, van Dongen GA, Stigter-van WM, et al., Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 2012; 11: 33-46.
36. Tseng W, Leong X, Engleman E,. Orthotopic mouse model of colorectal cancer. J Vis Exp 2007; 484.
37. Kim MP, Evans DB, Wang H, et al., Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4: 1670-80.
38. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al., The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009; 16: 2943-52.
39. Yamaguchi K, Enjoji M, Tsuneyoshi M,. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991; 47: 148-54.
40. Simeone DM, Ji B, Banerjee M, et al., Ceacam1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34: 436-43.
41. Ieda J, Yokoyama S, Tamura K, et al., Re-expression of ceacam1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer 2011; 129: 1351-61.
42. Lee YC, Boehm MK, Chester KA, et al., Reversible dimer formation and stability of the anti-tumour single-chain fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J Mol Biol 2002; 320: 107-27.
43. Hull EA, Livanos M, Miranda E, et al., Homogeneous bispecifics by disulfide bridging. Bioconjug Chem 2014; 8: 1395-401.
44. Tolner B, Smith L, Hillyer T, et al., From laboratory to phase I/II cancer trials with recombinant biotherapeutics. Eur J Cancer 2007; 43: 2515-22.
45. Choi HS, Nasr K, Alyabyev S, et al., Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. Angew Chem Int Ed Engl 2011; 50: 6258-63.
46. Choi HS, Gibbs SL, Lee JH, et al., Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat Biotechnol 2013; 31: 148-53.
47. Marshall MV, Draney D, Sevick-Muraca EM, et al., Single-dose intravenous toxicity study of IRDye 800CW in Sprague-dawley rats. Mol Imaging Biol 2010; 12: 583-94.
48. Valko K, Nunhuck S, Bevan C, et al., Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003; 92: 2236-48.
49. Rijpkema M, Oyen WJ, Bos D, et al., SPECT- and fluorescence Image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. J Nucl Med 2014; 55: 1519-24.
50. Keereweer S, Mol IM, Kerrebijn JD, et al., Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J Surg Oncol 2012; 105: 714-18.
51. Reagan-Shaw S, Nihal M, Ahmad N,. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
52. Scheuer W, van Dam GM, Dobosz M, et al., Drug-based optical agents: infiltrating clinics at lower risk. Sci Transl Med 2012; 4: 134ps11.
53. Sevick-Muraca EM, Zhu B,. The need for performance standards in clinical translation and adoption of fluorescence molecular imaging. Med Phys 2013; 40: 040402.